Related posts
Weekly 52-Week Low (or 52-Week High): CU-T, OLA-T, CP-T, DND-T and More 52-Week Highs and Lows (Mar 26-Apr 01)This summary was created by AI, based on 1 opinions in the last 12 months.
Evome Medical Technologies, previously known as Salona Global Medical, has undergone significant changes in recent times. The company has faced scrutiny due to its acquisition strategy in the physiotherapy sector, which has left it with a considerable amount of debt. However, new management is actively addressing this issue by selling off divisions to pay down debt, with the goal of eliminating all acquisition-related debt by late 2024 or early 2025. The introduction of new technology has led to equipment that is both smaller and more technologically advanced, allowing for potential mass sales. Encouragingly, the company's revenue has been ramping up, and EBITDA has turned positive, indicating a turnaround in financial performance. Moreover, Evome is exploring opportunities beyond North America, which could further enhance its market position.
Evome Medical Technologies is a Canadian stock, trading under the symbol EVMT-X on the TSX Venture Exchange (EVMT-CV). It is usually referred to as TSXV:EVMT or EVMT-X
In the last year, there was no coverage of Evome Medical Technologies published on Stockchase.
Evome Medical Technologies was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Evome Medical Technologies.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Evome Medical Technologies published on Stockchase.
On 2025-04-14, Evome Medical Technologies (EVMT-X) stock closed at a price of $0.005.
(Formerly Salona Global Medical, SGMD-X)
Acquisition strategy in physiotherapy, racked up a fair bit of debt. Market got concerned. New management, paying down some debt by selling off divisions. Goal is to get rid of all acquisition debt by late 2024/early 2025. New tech has made equipment smaller and more technology-driven, which will allow for mass sales.
Revenue ramping up, EBITDA has turned positive. Under the radar. Looking to do deals outside NA as well.